menu
    • menu
    [{"orgOrder":0,"company":"Bone Biologics","sponsor":"WallachBeth Capital","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2022","type":"Public Offering","leadProduct":"NELL1","moa":"IL-6 receptor","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Bone Biologics","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Bone Biologics \/ WallachBeth Capital","highestDevelopmentStatusID":"4","companyTruncated":"Bone Biologics \/ WallachBeth Capital"},{"orgOrder":0,"company":"Bone Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"rhNELL-1","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Bone Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bone Biologics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Bone Biologics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Bone Biologics

    Menu

    Bone Biologics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Bone Biologics

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed

                            Bone Biologics

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NELL1

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Preclinical

                            Sponsor : WallachBeth Capital

                            Deal Size : $5.1 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Bone Biologics Announces Closing of $5,100,000 Underwritten Public Offering

                            Details : The Company plans to use the net proceeds to fund its planned clinical trials for NELL-1, maintain and extend its patent portfolio, retain contract research organizations, and for working capital and other general corporate purposes.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            October 12, 2022

                            Lead Product(s) : NELL1

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Preclinical

                            Sponsor : WallachBeth Capital

                            Deal Size : $5.1 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Bone Biologics

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed

                            Bone Biologics

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : rhNELL-1

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bone Biologics Preclinical Study Shows rhNELL-1 Effectively Promotes Bone Formation

                            Details : Bone Biologics has completed a preclinical study, which shows its rhNELL-1 growth factor effectively promotes bone formation in a phylogenetically advanced spine model.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            January 08, 2020

                            Lead Product(s) : rhNELL-1

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth